Facial Hyperpigmentation
3
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Metformin
Research Leaders
5 sponsors active, led by Beiersdorf (Thailand) Co., Ltd.
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Topical Metformin Versus Triple Regimen for Epidermal Melasma
Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation
Research Network
Common Treatments
- Metformin1
- Test Cosmetic Product1
- Isobutylamidothiazolylresorcinol Cream 021
- Topical Triple Regimen1
- Vehicle1
Active Sponsors
- Beiersdorf (Thailand) Co., Ltd.1
- Kayuraeffect, LLP1
- Combined Military Hospital, Pakistan1
- Institute of Dermatology, Thailand1
- COD Research1
Top Investigators
Intra-group cooperation or coordination
Institute of Dermatology
Related Conditions
- Epidermal Melasma1